Vitamin D
Conditions
Brief summary
The primary objective of this study is to evaluate plasma concentrations of Vitamin D (25-hydroxyvitamin D; 1,25-dihydroxyvitamin D) of different Vitamin D formulations in healthy volunteers at two concentrations. Pharmacokinetic parameters (Serum 25(OH)D and 1,25(OH)2D ng/ml) are compared with those of a regular Vitamin D formulation and a new (microencapsulated) LipoMicel Vitamin D formulation. The secondary objective of this study is to evaluate safety blood parameters- The following blood parameters (serum levels) are checked: Alkaline Phosphatase, ALT, AST, Bilirubin, CRP, Creatinine, GGT. In addition, mineral levels-such as calcium, magnesium and phosphorus, potassium and sodium-are measured before and at the end of the study.
Detailed description
Study Design: At least 40 healthy volunteers of both sexes in the age range 21-65 participate in a parallel, randomized blinded study conducted with different vitamin D3 products. Each treatment is administered orally per day at a total dose of 1000 UI and 2500 IU vitamin d3 (cholecalciferol), together with breakfast, over a period of 30 days. Participants are randomly divided into 4 groups (at least 10 per group): The first group receives regular Vitamin D (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations (serum levels) of Vitamin D (25(OH)D and 1,25(OH)2D ng/ml are measured at baseline-before treatment start (day 0), during treatment (day 5, 10 and 15; one blood collection per day) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60. The entire study session will span the course of 60 days. Participants are asked to attend 7 visits at LifeLabs to collect venous blood samples. Each Vitamin D treatment is consumed with a glass of water along with breakfast for a period of 30 days. Safety blood work is performed upon study enrolment, at the end of the Vitamin supplementation (day 30)- and at the end of the study (day 60) at Life Labs. The following blood parameters are checked and must be within normal ranges to participate the study: Alkaline Phosphatase, ALT, AST, Bilirubin, CRP, Creatinine, GGT. Mineral levels-such as calcium, magnesium and phosphorus-are measured before and at the end of the study (day 30). All participants must understand written and spoken English and give written informed consent before any study specific procedure will be carried out. All tested products are formulation manufactured by Factors Group.
Interventions
DIETARY_SUPPLEMENTVitamin D3
Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.
Sponsors
Factors Group of Nutritional Companies Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Intervention model description
parallel, randomized blinded study
Eligibility
Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* age between 21 and 65 years; avoid consumption of any additional food supplements containing vitamin D; avoid use of tanning beds or other artificial UVB sources. Participants must complete an online questionnaire on their medical history, weight, height, lifestyle (smoking, exercising etc.) and dietary habits relating to food rich in vitamin D, including other dietary supplementations.
Exclusion criteria
* use of vitamin D, calcium, magnesium, fish oil, or omega 3 fatty acids supplements; history of acute or chronic illness (such as gastrointestinal, liver and kidney disorders, osteoporosis …); pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of Vitamin D serum level: change of 1,25-Dihydroxyvitamin D | at day 0 (before treatment), at day 5, 10, 15 (during treatment), at day 30 (end of treatment), at day 45 and 60 (after treatment). | Venous blood samples are collected to measure concentrations of 1,25-Dihydroxyvitamin D |
| Evaluation of Vitamin D serum level: change of 25-Hydroxyvitamin D | at day 0 (before treatment), at day 5, 10, 15 (during treatment), at day 30 (end of treatment), at day 45 and 60 (after treatment). | Venous blood samples are collected to measure concentrations of 25-Hydroxyvitamin D |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety blood work evaluation - change of alkaline phosphatase | at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment). | Venous blood samples are collected to measure concentrations of alkaline phosphatase |
| Safety blood work evaluation - change of bilirubin | at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment). | Venous blood samples are collected to measure concentrations of total bilirubin |
| Safety blood work evaluation - change of gamma-glutamyl transferase (GGT) | at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment). | Venous blood samples are collected to measure concentrations of GGT |
| Safety blood work evaluation - change of creatinine | at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment). | Venous blood samples are collected to measure concentrations of creatinine |
| Safety blood work evaluation - change of aspartate aminotransferase (AST) | at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment). | Venous blood samples are collected to measure concentrations of AST |
| Safety blood work evaluation - change of mineral levels such as calcium | at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment). | Venous blood samples are collected to measure concentrations of calcium |
| Safety blood work evaluation - change of mineral levels such as magnesium | at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment). | Venous blood samples are collected to measure concentrations of magnesium |
| Safety blood work evaluation - change of mineral levels such as phosphate | at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment). | Venous blood samples are collected to measure concentrations of phosphate |
| Safety blood work evaluation - change of mineral levels such as sodium | at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment). | Venous blood samples are collected to measure concentrations of sodium |
| Safety blood work evaluation - change of C Reactive Protein (CRP) | at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment). | Venous blood samples are collected to measure concentrations of CRP |
| Safety blood work evaluation - change of alanine aminotransferase (ALT) | at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment). | Venous blood samples are collected to measure concentrations of ALT |
Countries
Canada
Outcome results
None listed